Publications

An important output of the Register are the studies published in journals. Some of the publications to date show treatment effectiveness and safety data for crucial drugs, and themes include Drug survival and effectiveness, Baseline demographics and Risk of cancer in patients on biologics.

A full list of publications, with links to access the papers, can be found here:

# Title Authors Publication Year Journal
37 Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: A cohort study from Alabas OA, Mason KJ, Yiu ZZN, Warren RB, Lunt M, Smith CH, Griffiths, CEM; BADBIR Study Group BJD 2023 BJD
36 Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics Al-Janabi A, Eyre S, Foulkes AC, Khan AR, Dand N, Burova E, DeSilva B, Makrygeorgou, Davies E, Smith CH, Griffiths CEM, Morris AP, Warren RB; BSTOP & BADBIR Study Groups JID 2023 JID
35 Uptake of tumour necrosis factor - alpha inhibitor biosimilars for psoriasis: A drug utilisation study from BADBIR Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, Warren RB, Yiu ZZN; BADBIR Study Group BJD 2023 BJD
34 Effectiveness and persistence of acitretin, ciclosporin, fumaric acid esters and methotrexate for patients with moderate-to-severe psoriasis: a cohort study from BADBIR Alabas OA, Mason KJ, Yiu ZZN, Hampton PJ, Reynolds NJ, Owen CM, Bewley A, Laws PM, Warren RB, Lunt M, Smith CH, Griffiths CEM; BADBIR Study Group BJD 2023 BJD
33 Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using BADBIR Lada G, Chinoy H, Talbot PS, Warren RB, Kleyn CE; BADBIR Study Group SHD 2022 SHD
32 Drug Survival Associated With Effectiveness and Safety of Treatment With Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients With Psoriasis Yiu ZZN, Becher G, Kirby B, Laws P, Reynolds NJ, Smith CH, Warren RB, Griffiths CEM; BADBIR Study Group JAMA Dermatol 2022 JAMA Dermatol
31 Differences in Clinical Features and Comorbid Burden between HLA-C∗06:02 Carrier Groups in >9,000 People with Psoriasis Douroudis K, Ramessur R, Barbosa IA, Baudry D, Duckworth M, Angit C, Capon F, Chung R, Curtis CJ, Di Meglio P, Goulding JMR, Griffiths CEM, Lee SH, Mahil SK, Parslew R, Reynolds NJ, Shipman AR, Warren RB, Yiu ZZN, Simpson MA, Barker JN, Dand N, Smith CH; BADBIR; BSTOP Study Groups J Invest Dermatol 2022 J Invest Dermatol
30 Characteristics and skin cancer risk of psoriasis patients with a history of skin cancer in BADBIR Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ; Ormerod AD; BADBIR Study Group JEADV 2021 2021 JEADV
29 Defining Trajectories of Response in Psoriasis Patients Treated with Biologic Therapies Geifman N, Azadbakht N, Zeng J, Wilkinson T, Dand N, Buchan I, Stocken D, Di Meglio P, Warren RB, Barker JN; Reynolds NJ, Barnes MR, Smith CH, Griffiths CEM, Peek N; BADBIR Study Group, on behalf of the PSORT Consortium Br J Dermatol 2021 2021 Br J Dermatol
28 Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies Mason KJ, Burden AD, Barker J, Lunt M, Ali H, Kleyn CE, McElhone K, Soliman MM, Green AC, Griffiths CEM, Reynolds NJ, Ormerod AD JEADV 2021 2021 JEADV
27 Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models Jalali-Najafabadi F, Stadler M, Dand N, Jadon D, Soomro M, Ho P, Marzo-Ortega H, Helliwell P, Korendowych E, Simpson MA, Packham J, Smith CH, Barker JN, McHugh N, Warren RB, Barton A, Bowes J; BADBIR Study Group; BSTOP Study Group. Scientific Reports 2021 Scientific Reports
26 Using Real‐World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic‐Pharmacodynamic Study Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa‐Rajah A; Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Andrew Wright, Griffiths CEM, Reynolds NJ,Barker J, Warren RB, Burden AD, Theo Rispens , Joseph F Standing , Catherine H Smith; BADBIR Study Group; BSTOP Study Group; PSORT Consortium Clin Transl Sci 2020 2020 Clin Transl Sci
25 Risk of Major Cardiovascular Events in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study Rungapiromnan W, Mason KJ, Lunt M, McElhone K, Burden AD, Rutter MK, Warren RB, Griffiths CEM, Ashcroft DM; BADBIR Study Group J Eur Acad Dermatol Venereol 2020 2020 J Eur Acad Dermatol Venereol
24 Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) Mahil SK, Wilson N, Dand N, Reynolds NJ, Griffiths CEM, Emsley R, Marsden A, Evans I, Warren RB, Stocken D, Barker JN; Burden AD, Smith CH; BADBIR study group and the PSORT consortium Br J Dermatol 2020 2020 Br J Dermatol
23 The British Association of Dermatologists Biologics and Immunomodulators Register: a centenary celebration of research collaboration in British dermatology Yiu ZZN, Mason KJ, Smith CH, Griffiths CEM; BADBIR Study Group Br J Dermatol 2020 2020 Br J Dermatol
22 Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR) Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group Br J Dermatol 2020 2020 Br J Dermatol
21 Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register Yiu ZZN, Mason KJ, Hampton PJ, Reynolds NJ, Smith CH, Lunt M, Griffiths CEM, Warren RB; BADBIR Study Group JAMA Dermatol 2020 2020 JAMA Dermatol
20 HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis Dand N, Duckworth M, Baudry D, Russell A, Curtis CJ, Lee SH, Evans I, Mason KJ, Alsharqi A, Becher G, CEM Griffiths, Smith CH, Simpson MA, Barker JN; BSTOP Study Group; PSORT Consortium. J Allergy Clin Immunol 2019 2019 J Allergy Clin Immunol
19 Infliximab Is Associated With an Increased Risk of Serious Infection in Patients With Psoriasis in the U.K. And Republic of Ireland: Results From the British Association of Dermatologists Biologic Interventions Register (BADBIR) Yiu ZZN, Ashcroft DM, Evans I, McElhone K, Lunt M, Smith CH, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BSTOP Study Group Br J Dermatol 2019 2019 Br J Dermatol
18 Development and Validation of a Multivariable Risk Prediction Model for Serious Infection in Patients With Psoriasis Receiving Systemic Therapy Yiu ZZN, Sorbe C, Lunt M, Rustenbach SJ, Kühl L, Augustin M, Mason KJ, Ashcroft DM, Griffiths CEM, Warren RB; BSTOP Study Group Br J Dermatol 2019 2019 Br J Dermatol
17 Persistence and effectiveness of non-biologic systemic therapies for moderate‐to‐severe psoriasis in adults: a systematic review Mason KJ, Williams S, Yiu ZZN, McElhone K, Ashcroft DM, Kleyn CE, Jabbar-Lopez ZK, Owen CM, Reynolds NJ, Smith CH, Wilson N, Warren RB, Griffiths CEM Br J Dermatol 2019 2019 Br J Dermatol
16 Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis Tsakok T, Wilson N, Dand N, Loeff FC, Bloem K, Baudry D, Duckworth M, Pan S, Pushpa-Rajah A, Standing JF, de Vries A; BSTOP Study Group; PSORT Consortium. JAMA Dermatology 2019 2019 JAMA Dermatology
15 A Standardization Approach to Compare Treatment Safety and Effectiveness Outcomes Between Clinical Trials and Real-World Populations in Psoriasis Yiu ZZN, Mason KJ, Barker J, Hampton PJ, McElhone K, Smith CH, Warren RB, Griffiths CEM, Lunt M, Burden AD; BADBIR Study Group Br J Dermatol 2019 2019 Br J Dermatol
14 Differential drug survival of second-line biologic therapies in psoriasis patients: observational cohort study from the British Association of Dermatologists Biologic Interventions Register Iskandar IYK, Warren RB, Lunt M, Mason KJ, Evans I, McElhone K, Smith CH, Reynolds NJ, Ashcroft DM, Griffiths CEM; BADBIR Study Group J Invest Dermatol 2018 2018 J Invest Dermatol
13 Generating EQ-5D-3L Utility Scores from the Dermatology Life Quality Index: A Mapping Study in Patients with Psoriasis Davison NJ, Thompson AJ, Turner AJ, Longworth L, McElhone K, Griffiths CEM, Payne K; BADBIR Study Group Value Health 2018 2018 Value Health
12 Risk of Serious Infection in Patients With Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study From the British Association of Dermatologists Biologic Interventions Register (BADBIR) Yiu ZZN, Smith CH, Ashcroft DM, Lunt M, Walton S, Murphy R, Reynolds NJ, Ormerod AD, Griffiths CEM, Warren RB; BADBIR Study Group J Invest Dermatol 2018 2018 J Invest Dermatol
11 Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR Mason KJ, Barker J, Smith CH, Hampton PJ, Lunt M, McElhone K, Warren RB, Yiu ZZN, Griffiths CEM, Burden AD; BADBIR Study Group JAMA Dermatology 2018 2018 JAMA Dermatology
10 Cumulative exposure to biologics and risk of cancer in psoriasis patients: a meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland I Garcia-Doval; MA Descalzo; KJ Mason; AD Cohen; AD Ormerod; FJ Gómez-García; S Cazzaniga; I Feldhamer; H Ali; E Herrera-Acosta; CEM Griffiths; R Stern; L Naldi; Psonet Network. Br J Dermatol 2018 2018 Br J Dermatol
9 Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength Thorneloe RJ, Griffiths CEM, Emsley R, Ashcroft DM, Cordingley L; BADBIR Study Group; Psoriasis Stratification to Optimise Relevant Therapy Study Groups J Invest Dermatol 2018 2018 J Invest Dermatol
8 Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study Warren RB, Marsden A, Tomenson B, Mason KJ, Soliman MM, Burden AD, Reynolds NJ, Stocken D, Emsley R, Griffiths CEM, Smith CH; PSORT Consortium; BADBIR Study Group Br J Dermatol 2018 2018 Br J Dermatol
7 Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Iskandar IYK, Ashcroft DM, Warren RB, Evans I, McElhone K, Owen CM, Burden AD, Smith CH, Reynolds NJ, Griffiths CEM Br J Dermatol 2017 2017 Br J Dermatol
6 Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis Iskandar IYK, Ashcroft DM, Warren RB, Lunt M, McElhone K, Smith CH, Reynolds NJ, Griffiths CEM Br J Dermatol 2017 2017 Br J Dermatol
5 Identification of Factors That May Influence the Selection of First-Line Biological Therapy for People With Psoriasis: A Prospective, Multicentre Cohort Study Davison NJ, Warren RB, Mason KJ, McElhone K, Kirby B, Burden AD, Smith CH, Payne K, Griffiths CEM Br J Dermatol 2017 2017 Br J Dermatol
4 Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis Sawyer LM, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH PharmacoEconomics 2015 2015 PharmacoEconomics
3 Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR) Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, Lunt M, McElhone K, Ormerod AD, Owen CM; Reynolds NJ; Griffiths CEM; BADBIR Study Group J Invest Dermatol 2015 2015 J Invest Dermatol
2 Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register Iskandar IY, Ashcroft DM, Warren RB, Yiu ZZ, McElhone K, Lunt M, Barker JN, Burden AD, Ormerod AD, Reynolds NJ; Smith CH; Griffiths CEM. Br J Dermatol 2015 2015 Br J Dermatol
1 The British Association of Dermatologists Biologic Interventions Register (BADBIR): Design, Methodology and Objectives Burden AD, Warren RB, Kleyn CE, McElhone K, Smith CH, Reynolds NJ, Ormerod AD, Griffiths CE; BADBIR Study Group. Br J Dermatol 2012 2012 Br J Dermatol

Guidance for publishing BADBIR findings

Authorship

When publishing findings we suggest that authorship is discussed before starting to draft the publication so that there is consensus and the work of all contributors is suitably recognised.

The ICMJE criteria for authorship and the CREDIT taxonomy offer helpful information about the different contributions that are made when preparing publications.

We advise that the named authors on BADBIR papers are those who have:

  • 1) Made a relevant and substantial contribution to the conception and design, collection of data, or analysis and interpretation of the data
  • 2) Drafted the article or revised it critically for important intellectual content
  • 3) Provided final approval of the version to be published, in line with the Uniform Requirements for Manuscripts Submitted for Biomedical Journals

For publications based on BADBIR's active research questions list, the statement "on behalf of the BADBIR Study Group" is also to be included at the end of the named author list. Active research questions are the research questions that the Committee has approved and assigned to a group.

Full details can be found in our Authorship Policy.

How to acknowledge the BADBIR data

When findings from the BADBIR data are published, we request that the approved acknowledgement statements below are used so that the work of all contributors is suitably recognised.

The statement will depend on the category of the research. These are summarised below and full details can be found in our Authorship Policy.

Publication category Acknowledgement statement
1 For publications based on BADBIR's active research questions list

This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data and to participants who consent to being part of BADBIR.

The BADBIR Study Group comprises the BADBIR Steering Committee and the BADBIR Data Monitoring Committee (DCM). BADBIR Steering Committee members are: http://www.badbir.org/Clinicians/Information/SteeringCommittee.

Members of the DMC are: Prof Anja Strangfeld (Chair), Dr Girish Gupta, Imke Redeker and Dr Richard Weller.

2 For publications arising from independent investigators or BAD members

This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data and to participants who consent to being part of BADBIR.

The BADBIR Study Group comprises the BADBIR Steering Committee and the BADBIR Data Monitoring Committee (DCM). BADBIR Steering Committee members are: http://www.badbir.org/Clinicians/Information/SteeringCommittee.

Members of the DMC are: Prof Anja Strangfeld (Chair), Dr Girish Gupta, Imke Redeker and Dr Richard Weller.

3 For publications by pharmaceutical companies who are involved with BADBIR and are publishing an independent study

This paper is published with the dataset provided by BADBIR [http://www.badbir.org/]. BADBIR is one of the largest psoriasis registries in the world with over 20,000 registrations. We are grateful to all participating centres who contribute data and to participants who consent to being part of BADBIR.

Funding statement

The funding statement that should be used for all BADBIR publications can be found here.

Data availability statement

Some restrictions apply to the BADBIR, data meaning it may not be possible to make the data used in your publication available to others. Full details of this can be found here.

How to apply to use BADBIR data

If you are interested in applying to use BADBIR data to carry out some analysis, the details of how to apply can be found here.